# Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Study · id `cardio:ct-nct01508026` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01508026](<https://clinicaltrials.gov/study/NCT01508026>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01508026

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4161 participants.

## Technical summary

Registry record NCT01508026. Randomized; triple masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 4161 participants (enrolled count; ClinicalTrials.gov record NCT01508026, source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)
- Start date: 2012-01 (registry gives no type) (ClinicalTrials.gov record NCT01508026, source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)
- Primary completion: 2013-03 (actual) (ClinicalTrials.gov record NCT01508026, source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01508026, source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01508026, source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01508026-2014-04-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension
- Condition: Stage 1 Hypertension
- Condition: Stage 2 Hypertension
- Intervention (Drug): Nebivolol and Valsartan 1
- Intervention (Drug): Nebivolol and Valsartan 2
- Intervention (Drug): Nebivolol and Valsartan 3
- Intervention (Drug): Nebivolol 1
- Intervention (Drug): Nebivolol 2
- Intervention (Drug): Valsartan 1
- Intervention (Drug): Valsartan 2
- Intervention (Drug): Placebo
- Lead sponsor: Forest Laboratories
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Forest Laboratories (`cardio:org-forest-laboratories`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study (`cardio:pubmed-24881993`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 5bc28858d2f5990941f1d1858375846749e43dc1a3c68c357db3089a02ab5f6b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
